Partnerships ensure first mover advantage and
immediate revenue generation
TORONTO, Oct. 2, 2018 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), an integrated medical cannabis company with its core
operations in Colombia, announced
today that it has signed multi-channel distribution agreements for
Kuida®, its first CBD-based skincare brand. These agreements have
been secured with Colombia´s most recognized distributors in the
cosmeceutical industry.
Alvaro Torres, Khiron Co-founder
and Chief Executive Officer stated, "These key channel partnerships
enable us to execute our first go-to-market strategy, by entering
the $5.6 Billion Colombian skincare
market with significant distribution and access to large and
established consumer networks."
As part of a robust strategy, Kuida® launches with secured
distributor agreements that leverage their market reach, geographic
location, scale and ability to ensure the Kuida® brand achieves its
market potential. These agreements reflect retail, on-line and
wholesale distribution, and further the strategic goals of the
Company's wellness unit.
- Retail distribution: Kuida has entered into an exclusive
agreement with Farmatodo, one of Colombia´s largest pharmacy chains
with 56 stores and over 1.2 Million monthly transactions,
generating annual revenue of more than US $120 Million across more than 10 product
categories including, medicine, personal care, beauty and skin
care, and food and beverage, among others.
The exclusive agreement gives consumers direct product access based
on agreed prominent store merchandising and point of purchase
display across all Farmatodo stores. Following an exclusive period
with Farmatodo, Kuida will also be available at other leading
retail chains across the country.
- Online Distribution: Kuida has signed an agreement with
Farmalisto, Colombia's leading
digital drugstore with more than 800,000 monthly visits, sustained
annual sales growth of 150% and a strong presence in both
Colombia and Mexico. Farmalisto is a leading e-commerce
platform, based on a strong CRM program allowing patients and
consumers to access medicines and products with ease.
- Wholesale Distribution: Kuida has entered into an
agreement with Distribuciones AXA S.A., one of Colombia's largest national distributors in
the pharmaceutical sector, with 14.000 product SKU's and more than
8,000 retail clients. AXA will play an important role in Kuida´s
development, allowing the brand to reach an expanded network of
retailers and clients.
- Furthermore, Khiron's wellness unit has a robust e-commerce
strategy for Kuida that includes direct sales through
www.kuidaskincare.com
Kuida®, the first consumer brand of Khiron's wellness unit, is
the first in Colombia that brings
the benefits of Cannabidiol (CBD) to a comprehensive portfolio of
skin and body care products for women. Kuida® advances CBD and
innovative cosmeceutical ingredients to create our proprietary
CBDERM® technology, which is proven to be three times more
antioxidant than vitamin E, it has anti-aging properties, as well
as quick absorption and light textures to improve the penetration
of CBD within the skin.
Teodoro Zubillaga General Manager of Farmatodo stated "Having
witnessed how the retail market in Colombia has evolved, how new players and
brands have arrived, Khiron seeks a great opportunity in the market
with an innovative product portfolio. We are sure that Kuida® will
be a success with our clients"
José Joaquin Mora CEO & CO-Founder of Farmalisto stated,
"The strategic alliance between Khiron and Farmalisto allows
immediate delivery of CBD cosmeceutical products of the highest
quality. Kuida®´s products will be available through an
innovative e-commerce platform that Farmalisto offers, providing
consumers with innovative products delivered with leading
commercial technology provided through the most innovative digital
platform".
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXv: KRHN, OTCQB: KHRNF,
Frankfurt: A2JMZC) ("Khiron" or
the "Company") is positioned to be the dominant integrated medical
cannabis company in Latin America.
Khiron has core operations in Colombia and is fully licensed in the country
for the cultivation, production, domestic distribution, and
international export of both tetrahydrocannabinol (THC) and
cannabidiol (CBD) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
the first Colombian based medical cannabis company to trade on any
exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found
at www.khiron.ca.
Forward-Looking Statements
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Readers are cautioned to
not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Filing Statement which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.